A multi-center, randomized, vitamin E controlled and opening clinical trial of selegiline in patients with Parkinson's disease

Chinese Journal of Neurology

Volumn 37, Issue 5, 2004, Pages 413-416

  Su, Wen ^a   Chen, Hai Bo ^a   Zhang, Zhen Xin ^a   Chen, Biao ^a   Wang, Lu Ning ^a   Sun, Xiang Ru ^a   Shen, Yang ^a   Li, Yi ^a   Geng, Tong Chao ^a   Zhao, Wei Qin ^a   Zhang, Xiao Ying ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Monoamine oxidase inhibitors; Multi center, studies; Parkinson disease; Randomized controlled trials; Selegiline

Indexed keywords

ALPHA TOCOPHEROL; SELEGILINE;

ADULT; AGED; ARM MOVEMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAMILTON SCALE; HOEHN YAHR STAGING SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 19944396137     PISSN: 10067876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol, 2002, 51: 604-612.
2. Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Acta Neurol Scand Suppl, 1993, 146: 3642.
3. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology, 1998, 51: 520-525.
4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 1988, 51: 745-752.
5. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD. Neurology, 1999, 53: 573-579.
6. Jansen Steur EN, Ballering LA. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Adv Neurol, 1999, 80: 505-508.
7. Steur EN, Ballering LA. Moclobemide and selegiline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry, 1997, 63: 547.
8. Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology, 2000, 55: 1785-1789.